Biogen struck a deal Tuesday to buy Apellis Pharmaceuticals for $5.6 billion. The buyout adds two approved drugs to Biogen's ...

During the last three months, 21 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their ...

The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates. 10 stocks we like better ...

Apellis Pharmaceuticals (APLS) stock jumped 136% after Biogen's $5.6B acquisition offer at $41/share, representing a 140% premium to previous close.

In the latest quarter, 9 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...

Biogen ( (BIIB)) has issued an update. On March 11, 2026, Biogen Inc. announced that its Chief Legal Officer, Susan H. Alexander, will leave the company at the end of May 2026, marking a significant ...

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

Despite recording better-than-expected Q4 2025 financials, Biogen (BIIB) on Friday projected a mid-single-digit percentage decline in revenue for 2026 compared to last year amid pressure on its ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both ...